These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1155 related articles for article (PubMed ID: 20141835)

  • 1. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
    Heidorn SJ; Milagre C; Whittaker S; Nourry A; Niculescu-Duvas I; Dhomen N; Hussain J; Reis-Filho JS; Springer CJ; Pritchard C; Marais R
    Cell; 2010 Jan; 140(2):209-21. PubMed ID: 20141835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raf inhibitors target ras spatiotemporal dynamics.
    Cho KJ; Kasai RS; Park JH; Chigurupati S; Heidorn SJ; van der Hoeven D; Plowman SJ; Kusumi A; Marais R; Hancock JF
    Curr Biol; 2012 Jun; 22(11):945-55. PubMed ID: 22560614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
    Rebocho AP; Marais R
    Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of RAF family kinases: new insights from recent structural and biochemical studies.
    Spencer-Smith R; Morrison DK
    Biochem Soc Trans; 2024 Jun; 52(3):1061-1069. PubMed ID: 38695730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
    Wang P; Laster K; Jia X; Dong Z; Liu K
    Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1
    Kim J; Choi B; Im D; Jung H; Moon H; Aman W; Hah JM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1314-1320. PubMed ID: 31307243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.
    Riaud M; Maxwell J; Soria-Bretones I; Dankner M; Li M; Rose AAN
    Nat Rev Cancer; 2024 Feb; 24(2):105-122. PubMed ID: 38195917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma.
    Wu KJ; Ho SH; Wu C; Wang HD; Ma DL; Leung CH
    J Cell Mol Med; 2021 Feb; 25(4):1972-1981. PubMed ID: 33377602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis.
    Pedersen M; Viros A; Cook M; Marais R
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1162-6. PubMed ID: 25043451
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction.
    Durrant DE; Smith EA; Goncharova EI; Sharma N; Alexander PA; Stephen AG; Henrich CJ; Morrison DK
    Mol Cancer Ther; 2021 Sep; 20(9):1743-1754. PubMed ID: 34158349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RASopathy mutations provide functional insight into the BRAF cysteine-rich domain and reveal the importance of autoinhibition in BRAF regulation.
    Spencer-Smith R; Terrell EM; Insinna C; Agamasu C; Wagner ME; Ritt DA; Stauffer J; Stephen AG; Morrison DK
    Mol Cell; 2022 Nov; 82(22):4262-4276.e5. PubMed ID: 36347258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation.
    Trebino TE; Markusic B; Nan H; Banerjee S; Wang Z
    Elife; 2023 Dec; 12():. PubMed ID: 38150000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation.
    Trebino T; Markusic B; Nan H; Banerjee S; Wang Z
    bioRxiv; 2023 Sep; ():. PubMed ID: 37163002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
    Dahlman KB; Xia J; Hutchinson K; Ng C; Hucks D; Jia P; Atefi M; Su Z; Branch S; Lyle PL; Hicks DJ; Bozon V; Glaspy JA; Rosen N; Solit DB; Netterville JL; Vnencak-Jones CL; Sosman JA; Ribas A; Zhao Z; Pao W
    Cancer Discov; 2012 Sep; 2(9):791-7. PubMed ID: 22798288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA;
    N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
    Sen B; Peng S; Tang X; Erickson HS; Galindo H; Mazumdar T; Stewart DJ; Wistuba I; Johnson FM
    Sci Transl Med; 2012 May; 4(136):136ra70. PubMed ID: 22649091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
    Yao Z; Yaeger R; Rodrik-Outmezguine VS; Tao A; Torres NM; Chang MT; Drosten M; Zhao H; Cecchi F; Hembrough T; Michels J; Baumert H; Miles L; Campbell NM; de Stanchina E; Solit DB; Barbacid M; Taylor BS; Rosen N
    Nature; 2017 Aug; 548(7666):234-238. PubMed ID: 28783719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
    Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
    Yao Z; Torres NM; Tao A; Gao Y; Luo L; Li Q; de Stanchina E; Abdel-Wahab O; Solit DB; Poulikakos PI; Rosen N
    Cancer Cell; 2015 Sep; 28(3):370-83. PubMed ID: 26343582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.